Vofatamab clinical trials
Also written MFGR1877S and B-701.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses vofatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Genentech, Inc. (2) · Rainier Therapeutics (2) · Fusion Pharmaceuticals Inc. (1) · Mark Pomerantz, MD (1)
Often tested with
Tested in the same studies.
Actinium Ac 225 Vofatamab (1) · Indium In 111 Vofatamab (1)
Studies
Open first, then newest update. How each study uses vofatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedPhase 1/2Fusion Pharmaceuticals Inc.NCT05363605Written as vofatamab
- A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell CarcinomaTerminatedPhase 1/2Rainier TherapeuticsNCT03123055Written as B-701
- Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell CarcinomaTerminatedPhase 1/2Rainier TherapeuticsNCT02401542Written as Vofatamab
- Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial TractTerminatedPhase 1Mark Pomerantz, MDNCT02925533Written as B-701
- Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsCompletedPhase 1Genentech, Inc.NCT01363024Written as MFGR1877S
- A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple MyelomaCompletedPhase 1Genentech, Inc.NCT01122875Written as MFGR1877S
Codes
What other systems call vofatamab · ClinicalTrials.gg INT006105
- MeSH (NLM) C573866vofatamabOne source NLM
- UNII (FDA) JMH6YR91PGVOFATAMABConfirmed FDA, NLM
- NCI Thesaurus C116863VofatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C573866 | vofatamab | One source NLM |
| UNII (FDA) | JMH6YR91PG | VOFATAMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C116863 | Vofatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.